

Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

Feng Zhang*,¹ Yuxian Bai,² Weijia Fang,³ Zhiqiang Meng,⁴ Jianping Xiong,⁵ Yabing Guo,⁶ Tao Zhang,⁷ Jingdong Zhang,⁸ Jieer Ying,⁹ Zhendong Chen,¹⁰ Zhenggang Ren,¹¹ Yajin Chen,¹² Chunyi Hao,¹³ Liu Yang,¹⁴ Jun Wang,¹⁵ Juan Zhang,¹⁵ Fan Yu,¹⁴ Xikun Wu,¹⁴ Shukui Qin¹⁶¹Hubei Cancer Hospital, Wuhan, China; ²Harbin Medical University Cancer Hospital, Harbin, China; ³The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China; ⁴Fudan University Shanghai Cancer Center, Shanghai, China; ⁵The First Affiliated Hospital of Nanchang University, Nanchang, China; ⁶Nanfang Hospital, Southern Medical University, Guangzhou, China; ⁷Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; ⁸Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, China; ⁹Zhejiang Cancer Hospital, Hangzhou, China; ¹⁰The Second Hospital of Anhui Medical Hospital, Hefei, China; ¹¹Zhongshan Hospital, Fudan University, Shanghai, China; ¹²Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; ¹³Beijing Cancer Hospital, Beijing, China; ¹⁴BeiGene (Shanghai) Co., Ltd., Shanghai, China; ¹⁵BeiGene (Beijing) Co., Ltd., Beijing, China; ¹⁶Cancer Center, Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China. *Presenting author; †Corresponding author.

Conclusions

- Treatment with sitravatinib plus tislelizumab showed efficacy and a manageable safety/tolerability profile in patients with pretreated, advanced HCC
- Sitravatinib plus tislelizumab demonstrated antitumor activity in previously treated patients with anti-PD-1/PD-L1 antibody-naïve and refractory HCC, with an ORR of 9.5% vs 10.5%, DCR of 85.7% vs 84.2%, and PFS of 6.8 months vs 4.8 months in Cohort B and Cohort C, respectively
- An increase in sVEGF and IP-10, and decrease in sVEGFR2 was observed in both cohorts after treatment with tislelizumab plus sitravatinib
- Further investigation of sitravatinib plus tislelizumab in these patient populations is warranted


Background

- Combination therapy has shown promising activity in recent studies of patients with hepatocellular carcinoma (HCC).¹⁻³ However, some patients will not have a durable response.³ Treatment options after prior immunotherapy in HCC remain a significant unmet medical need
- Tislelizumab is a humanized IgG4 anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has high affinity and specificity for PD-1 and was designed to minimize FcγR binding on macrophages to abrogate antibody-dependent phagocytosis, a potential mechanism of resistance.^{4,6} Sitravatinib is a selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MER) and split tyrosine-kinase domain-containing receptors (vascular endothelial growth factor receptor 2 [VEGFR2], KIT) that can alter a tumor's immune landscape to favor immune checkpoint blockade and overcome resistance.⁷ This may help to overcome an immunosuppressive tumor microenvironment and augment antitumor responses
- This multi-cohort, phase 1/2 study assessed the safety/tolerability and efficacy of sitravatinib alone or with tislelizumab (BGB-900-104; NCT03941873). We report results from the phase 2 cohorts of patients with HCC receiving sitravatinib plus tislelizumab

Methods

- An open-label, multicenter, non-randomized, multi-cohort, phase 2 trial was conducted (NCT03941873)
- Study design and endpoints are summarized in Figure 1

Figure 1. Study Design



Results

Patients

- As of July 12, 2021, 43 patients across both cohorts were treated in the study, and 10 patients remained on treatment. Median follow-up time was 8.6 months (range: 0.7-10.6). In total, there were 43 patients in the safety analysis set, and 40 patients in the efficacy analysis set
- Baseline characteristics are summarized in Table 1

Table 1. Demographics and Baseline Characteristics (Safety Analysis Set; N=43)

		Cohort B (n=21)	Cohort C (n=22)	Total (N=43)
Age, years	Median (range)	62.0 (30, 70)	49.5 (29, 71)	55.0 (29, 71)
Sex, n (%)	Male	18 (85.7)	20 (90.9)	38 (88.4)
	Female	3 (14.3)	2 (9.1)	5 (11.6)
Race, n (%)	Asian	21 (100.0)	22 (100.0)	43 (100.0)
	0	14 (66.7)	13 (59.1)	27 (62.8)
ECOG PS, n (%)	1	7 (33.3)	9 (40.9)	16 (37.2)
	Stage B	8 (38.1)	3 (13.6)	11 (25.6)
BCLC stage at study entry, n (%)	Stage C	13 (61.9)	19 (86.4)	32 (74.4)
	1	15 (71.4)	14 (63.6)	29 (67.4)
Number of prior treatment lines, ^a n (%)	2	6 (28.6)	8 (36.4)	14 (32.6)
	HBV infection status, n (%)	Positive	3 (14.3)	3 (13.6)
HCV infection status, n (%)	Positive	0 (0.0)	0 (0.0)	0 (0.0)
Macrovascular invasion, n (%)	Yes	2 (9.5)	2 (9.1)	4 (9.3)
Extrahepatic spread, n (%)	Yes	13 (61.9)	17 (77.3)	30 (69.8)

^aPercentage was based on patients with prior anticancer systemic therapy.

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C infection.

Efficacy

- The confirmed objective response rate (ORR) was 9.5% in two patients in Cohort B and 10.5% in two patients in Cohort C, all of whom achieved partial responses (Table 2). Best change in target lesion for both cohorts is presented in Figure 2
- Disease control rate (DCR) was 85.7% (95% CI: 63.7, 97.0) in Cohort B and 84.2% (95% CI: 60.4, 96.6) in Cohort C (Table 2)
- Median progression-free survival (PFS) was 6.8 months (95% CI: 2.8, 8.4) and 4.8 months (95% CI: 2.7, 6.8) in Cohort B and Cohort C, respectively (Figure 3a). Overall survival (OS) is presented in Figure 3b. The landmark OS rate at 9 months was 71.4% (95% CI: 47.2, 86.0) and 52.7% (95% CI: 23.2, 75.5) in Cohort B and Cohort C, respectively

Table 2. Analysis of Confirmed Disease Response per RECIST v1.1 (Efficacy Analysis Set; N=40)

	Cohort B (n=21)	Cohort C (n=19)	Total (N=40)
ORR, % (95% CI)	9.5 (1.2, 30.4)	10.5 (1.30, 33.1)	10.0 (2.8, 23.7)
Best overall response, n (%)			
Complete response	0 (0.0)	0 (0.0)	0 (0.0)
Partial response	2 (9.5)	2 (10.5)	4 (10.0)
Stable disease	16 (76.2)	14 (73.7)	30 (75.0)
Progressive disease	3 (14.3)	2 (10.5)	5 (12.5)
Not evaluated ^a	0 (0.0)	1 (5.3)	1 (2.5)
DCR, % (95% CI)	85.7 (63.7, 97.0)	84.2 (60.4, 96.6)	85.0 (70.2, 94.3)

^aOne patient was not evaluated for best overall response due to "unexplained death" before the first tumor assessment.

Abbreviations: CI, confidence interval; DCR, disease control rate; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.

Safety

- Median duration of exposure was 18.3 weeks (range: 0.3-45.1) for sitravatinib and 18.3 weeks (range: 3.0-48.1) for tislelizumab
- In total, 42 patients (97.7%) had ≥1 treatment-emergent adverse event (TEAE), and 37 patients (86.0%) had ≥1 treatment-related AE (TRAE) (Table 3)
- There were two TRAEs leading to death (hepatic encephalopathy in Cohort B and unexplained death in Cohort C) (Table 3)
- In total, 26 patients (60.5%) experienced ≥1 TEAE leading to dose modification of sitravatinib; and 16 patients (37.2%) experienced ≥1 TEAE leading to dose modification of tislelizumab (Table 3). The TEAEs leading to sitravatinib discontinuation were hemoptysis, hepatic encephalopathy, pneumonia, and proteinuria and for tislelizumab discontinuation: death, hemoptysis, hepatic encephalopathy, and rash (all n=1, [2.3%])
- The most frequently observed TEAEs were increase in alanine aminotransferase (53.5%), increase in aspartate aminotransferase (53.5%), and palmar-plantar erythrodysesthesia (51.2%) (Table 4). The most frequently observed ≥ Grade 3 TEAEs were palmar-plantar erythrodysesthesia (9.3%) and decrease in platelet count (7.0%)
- The safety profile of sitravatinib plus tislelizumab was similar across patients in Cohort B and Cohort C

Figure 2. Change in Target Lesion by Investigator-Assessed Confirmed Best Overall Response (Efficacy Analysis Set; N=40)




Figure 3. Progression-Free Survival and Overall Survival (Efficacy Analysis Set; N=40)




Table 3. Combined Summary of AEs in Cohorts B and C (Safety Analysis Set; N=43)

Patients, n (%)	TEAEs	TRAEs
Patients with ≥1 AE	42 (97.7)	37 (86.0)
Serious	12 (27.9)	7 (16.3)
≥ Grade 3	21 (48.8)	17 (39.5)
≥ Grade 3 serious	9 (20.9)	6 (14.0)
AEs leading to death	3 (7.0)	2 (4.7)
AEs leading to sitravatinib discontinuation	4 (9.3)	4 (9.3)
AEs leading to tislelizumab discontinuation	4 (9.3)	4 (9.3)
AEs leading to sitravatinib dose modification ^a	26 (60.5)	24 (55.8)
AEs leading to tislelizumab dose modification ^b	16 (37.2)	13 (30.2)

^aAEs leading to sitravatinib dose modification included dose reduction and/or interruption; ^bAEs leading to tislelizumab dose modification included dose delay and/or interruption.

Abbreviations: AE, adverse event; TEAE, treatment-emergent AE; TRAE, treatment-related AE.

Table 4. Combined Summary of TEAEs With ≥15% Frequency in Cohorts B and C (Safety Analysis Set; N=43)

Event, n (%)	Any Grade	≥ Grade 3
Alanine aminotransferase increased	23 (53.5)	1 (2.3)
Aspartate aminotransferase increased	23 (53.5)	1 (2.3)
Palmar-plantar erythrodysesthesia	22 (51.2)	4 (9.3)
Proteinuria	20 (46.5)	1 (2.3)
Diarrhea	18 (41.9)	1 (2.3)
Hypertension	14 (32.6)	1 (2.3)
Blood creatine phosphokinase increased	10 (23.3)	1 (2.3)
Blood thyroid stimulating hormone increased	10 (23.3)	0 (0.0)
Decreased appetite	10 (23.3)	0 (0.0)
Platelet count decreased	9 (20.9)	3 (7.0)
Hypoalbuminemia	8 (18.6)	0 (0.0)
Vomiting	8 (18.6)	0 (0.0)
White blood cell count decreased	8 (18.6)	0 (0.0)
Abdominal pain upper	7 (16.3)	0 (0.0)
Alpha hydroxybutyrate dehydrogenase increased	7 (16.3)	0 (0.0)
Blood bilirubin increased	7 (16.3)	0 (0.0)
Blood lactate dehydrogenase increased	7 (16.3)	0 (0.0)

Abbreviation: TEAE, treatment-emergent adverse event.

Pharmacodynamic biomarkers

- Changes from baseline (Cycle 1 Day 1, [C1D1]) in blood-based biomarkers were assessed. A trend towards an increase in soluble VEGF (sVEGF) and interferon gamma-induced protein 10 (IP-10), and a decrease in sVEGFR2 was observed after treatment with tislelizumab combined with sitravatinib in both cohorts at all post-treatment visits (Table 5)

Table 5. Change From Baseline in Pharmacodynamic Biomarkers

Biomarker	C2D1		C3D1		
	Estimated Mean Fold Change From C1D1 (95% CI)	Patients, n	Estimated Mean Fold Change From C1D1 (95% CI)	Patients, n	
Cohort B	sVEGF	2.9 (2.0, 4.1)	18	2.6 (1.6, 4.3)	16
	sVEGFR2	0.7 (0.6, 0.8)	18	0.8 (0.7, 0.9)	16
	IP-10	1.5 (1.2, 1.8)	18	1.4 (1.1, 1.7)	16
Cohort C	sVEGF	3.8 (2.9, 5.0)	15	3.6 (2.4, 5.4)	13
	sVEGFR2	0.6 (0.6, 0.7)	15	0.7 (0.6, 0.7)	13
	IP-10	1.2 (0.8, 1.6)	15	1.4 (1.0, 1.9)	13

Baseline was at C1D1. The mean fold change was estimated from a linear mixed model of repeated measurements. An increase from baseline was a fold change of >1 at C2D1 or C3D1; a decrease from baseline was a fold change of <1 at C2D1 or C3D1. Abbreviations: C, cycle; CI, confidence interval; D, day; IP-10, interferon gamma-induced protein 10; sVEGFR2, soluble vascular endothelial growth factor receptor 2.

References

- Ikeda M, et al. *J Clin Oncol*. 2018;15(suppl):4076.
- Stein S, et al. *J Clin Oncol*. 2018;15(suppl):4074.
- Xu J, et al. *Clin Cancer Res*. 2018;25:515-523.
- Zhang T, et al. *Cancer Immunol Immunother*. 2018;67:1079-1090.
- Dahan R, et al. *Cancer Cell*. 2015;28:285-295.
- Feng Y, et al. *ASCO* 2019 (Abstract 4048).
- Du W, et al. *JCI Insight*. 2018;3:e124184.

Acknowledgments

Medical writing support for the development of this poster and associated abstract, under direction of the authors, was provided by Tamsin Grewal, MSc, of Ashfield MedComms, an Inizio company, and was funded by BeiGene Ltd.

*Author contact details: qinsk@cSCO.org.cn (Shukui Qin)